Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35580269

Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Aug 11
First author
Yamamoto C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Aug 11;140(6):525-526. doi: 10.1182/blood.2022016958.
    note
    Source null
    related pmid
    35951343
    relationship
    Comment in

Authors and identifiers

  1. name
    Yamamoto C
    type
    Author
  2. name
    Minakata D
    type
    Author
  3. name
    Koyama S
    type
    Author
  4. name
    Sekiguchi K
    type
    Author
  5. name
    Fukui Y
    type
    Author
  6. name
    Murahashi R
    type
    Author
  7. name
    Nakashima H
    type
    Author
  8. name
    Matsuoka S
    type
    Author
  9. name
    Ikeda T
    type
    Author
  10. name
    Kawaguchi SI
    type
    Author
  11. name
    Toda Y
    type
    Author
  12. name
    Ito S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Yamamoto C
    type
    Author
  2. name
    Minakata D
    type
    Author
  3. name
    Koyama S
    type
    Author
  4. name
    Sekiguchi K
    type
    Author
  5. name
    Fukui Y
    type
    Author
  6. name
    Murahashi R
    type
    Author
  7. name
    Nakashima H
    type
    Author
  8. name
    Matsuoka S
    type
    Author
  9. name
    Ikeda T
    type
    Author
  10. name
    Kawaguchi SI
    type
    Author
  11. name
    Toda Y
    type
    Author
  12. name
    Ito S
    type
    Author
bibliography ids
  1. nci-bib-2edf45c12302d42868839e01
book metadata
content sha256
47ff3bb71ac051fb8d35768f0f12638e731f6f6540dba679ab2f3c0c3828d99e
document type
citation
dois
  1. 10.1182/blood.2021015220
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35580269
immutable id
pubmed:35580269@47ff3bb71ac051fb8d35768f0f12638e731f6f6540dba679ab2f3c0c3828d99e
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
6
name
Blood
nlm unique id
7603509
pages
594-607
volume
140
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Aug 11;140(6):525-526. doi: 10.1182/blood.2022016958.
    note
    Source null
    related pmid
    35951343
    relationship
    Comment in
outcomes validated
false
pmid
35580269
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
ecd7675f63ae92d50cd6801b09f4cfb0ebc980e92722810eb8e57383c6145352
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Aug 11
precision
day
year
2022
publication types
  1. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35580269/
title
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.

Preserved source evidence · Not medical advice